Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Detrimental Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: New Insights from Umbria Atrial Fibrillation Registry.

Angeli F, Reboldi G, Trapasso M, Aita A, Ambrosio G, Verdecchia P.

Medicina (Kaunas). 2019 Jul 9;55(7). pii: E358. doi: 10.3390/medicina55070358.

2.

Response by Verdecchia et al to Letter Regarding Article "Sudden Cardiac Death in Hypertensive Patients".

Verdecchia P, Angeli F, Cavallini C, Reboldi G.

Hypertension. 2019 Jul 1:HYPERTENSIONAHA11913441. doi: 10.1161/HYPERTENSIONAHA.119.13441. [Epub ahead of print] No abstract available.

PMID:
31256716
3.

Tight Blood Pressure Control Saves Lives in Hypertensive Patients With Chronic Kidney Disease.

Angeli F, Verdecchia P, Reboldi G.

Hypertension. 2019 Jun;73(6):1172-1173. doi: 10.1161/HYPERTENSIONAHA.119.12855. No abstract available.

PMID:
31067201
4.

Managing hypertension in 2018: which guideline to follow?

Angeli F, Reboldi G, Trapasso M, Aita A, Verdecchia P.

Heart Asia. 2019 Feb 22;11(1):e011127. doi: 10.1136/heartasia-2018-011127. eCollection 2019.

5.

Sudden Cardiac Death in Hypertensive Patients.

Verdecchia P, Angeli F, Cavallini C, Aita A, Turturiello D, De Fano M, Reboldi G.

Hypertension. 2019 May;73(5):1071-1078. doi: 10.1161/HYPERTENSIONAHA.119.12684.

PMID:
30827144
6.

European and US guidelines for arterial hypertension: similarities and differences.

Angeli F, Reboldi G, Trapasso M, Gentile G, Pinzagli MG, Aita A, Verdecchia P.

Eur J Intern Med. 2019 May;63:3-8. doi: 10.1016/j.ejim.2019.01.016. Epub 2019 Feb 4. Review.

PMID:
30732939
7.

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.

Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L.

J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.

8.

Keep Blood Pressure Low, but Not Too Much….

Verdecchia P, Angeli F, Cavallini C, Reboldi G.

Circ Res. 2018 Nov 9;123(11):1205-1207. doi: 10.1161/CIRCRESAHA.118.314017. No abstract available.

PMID:
30571468
9.

[What are the main novelties in the recent US and European guidelines for the management of hypertension?]

Verdecchia P, Angeli F, Cavallini C, Ambrosio G, Aita A, Turturiello D, Reboldi G.

G Ital Cardiol (Rome). 2018 Nov;19(11):611-619. doi: 10.1714/3012.30108. Italian. No abstract available.

PMID:
30425390
10.

Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.

Angeli F, Trapasso M, Signorotti S, Verdecchia P, Reboldi G.

Expert Rev Clin Pharmacol. 2018 Nov;11(11):1073-1084. doi: 10.1080/17512433.2018.1540299. Epub 2018 Nov 3. Review.

PMID:
30362840
11.

Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.

Verdecchia P, Vedovati MC, Conti S, Giustozzi M, Aita A, Molini G, Angeli F, Turturiello D, Becattini C, Cavallini C, Agnelli G.

Expert Opin Drug Saf. 2018 Nov;17(11):1063-1069. doi: 10.1080/14740338.2018.1529166. Epub 2018 Oct 8.

PMID:
30260252
12.

Gathering evidence on the prognostic role of central blood pressure in hypertension.

Angeli F, Reboldi G, Trapasso M, Aita A, Verdecchia P.

Hypertens Res. 2018 Nov;41(11):865-868. doi: 10.1038/s41440-018-0108-3. Epub 2018 Sep 26. No abstract available.

PMID:
30258171
13.

What to Do When Blood Pressure Is Between 130/80 and 139/89 mm Hg?

Verdecchia P, Angeli F, Reboldi G.

J Am Coll Cardiol. 2018 Sep 11;72(11):1198-1200. doi: 10.1016/j.jacc.2018.07.010. No abstract available.

PMID:
30189995
14.

The 2018 ESC/ESH hypertension guidelines: Should nephrologists always stop at the lower boundary?

Reboldi G, Gentile G, Angeli F, Verdecchia P.

J Nephrol. 2018 Oct;31(5):621-626. doi: 10.1007/s40620-018-0526-y. Epub 2018 Aug 30.

PMID:
30168081
15.

[Evaluation of cardiovascular risk and perioperative management of patients undergoing noncardiac surgery. Results of an ANMCO web survey].

Pilleri A, Abrignani MG, Angeli F, Fontanive P, Silvestri P, Mureddu GF.

G Ital Cardiol (Rome). 2018 Sep;19(9):504-509. doi: 10.1714/2951.29669. Italian.

PMID:
30087511
16.

Heart failure, pulse pressure and heart rate: Refining risk stratification.

Angeli F, Reboldi G, Verdecchia P.

Int J Cardiol. 2018 Nov 15;271:206-208. doi: 10.1016/j.ijcard.2018.07.072. Epub 2018 Jul 17. No abstract available.

PMID:
30029799
17.

Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease.

Angeli F, Gentile G, Trapasso M, Verdecchia P, Reboldi G.

J Hum Hypertens. 2018 Sep;32(8-9):625-632. doi: 10.1038/s41371-018-0081-y. Epub 2018 Jun 13.

PMID:
29899374
18.

PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.

Angeli F, Verdecchia P, Trapasso M, Pane M, Signorotti S, Reboldi G.

Expert Opin Drug Metab Toxicol. 2018 May;14(5):533-541. doi: 10.1080/17425255.2018.1468435. Epub 2018 May 10. Review.

PMID:
29676941
19.

Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies.

Verdecchia P, Angeli F, Reboldi G.

Circ Res. 2018 Jan 19;122(2):352-368. doi: 10.1161/CIRCRESAHA.117.311402. Review.

PMID:
29348255
20.

The Tale of an Innocent: Intensive Treatment and the J-Curve in the SPRINT Trial (Systolic Blood Pressure Intervention Trial).

Verdecchia P, Angeli F, Reboldi G.

Circulation. 2017 Dec 5;136(23):2230-2232. doi: 10.1161/CIRCULATIONAHA.117.030791. No abstract available.

PMID:
29203565

Supplemental Content

Loading ...
Support Center